Semaglutide Plus Dapagliflozin: Short-Term Gains in Diabetic CKD

This retrospective single-center cohort suggests additive 8-week metabolic, inflammatory, and surrogate renal improvements with combination semaglutide and dapagliflozin in type 2 diabetes with chronic kidney disease, but offers no hard renal outcome data for nephrology pharmacists to act on.

📅 Journal publication: Oct 9, 2026 · Last updated: Oct 11, 2026

semaglutidedapagliflozinGLP-1 receptor agonistSGLT2 inhibitortype 2 diabetes mellituschronic kidney diseasediabetic kidney diseasecombination therapyretrospective cohorths-CRPproteinuria Nephrology / Renal Pharmacy

Background Information

Could combining semaglutide and dapagliflozin benefit diabetic patients with kidney disease?

Patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) face significant health challenges. Combining semaglutide with dapagliflozin may offer therapeutic benefits. The combination treatment showed greater reductions in glycemic indices, renal function parameters, and inflammatory markers compared to monotherapy, with no increase in adverse events over 8 weeks. The study's retrospective design and short duration limit its impact, but it suggests potential benefits of combining these agents for T2DM with CKD. Combining semaglutide and dapagliflozin improves glycemic and renal parameters short-term in T2DM with CKD.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Gong C, Luo Q, Li Q

Citation: Gong C, Luo Q, Li Q Short-term clinical efficacy and recorded adverse events of semaglutide combined with dapagliflozin in patients with type 2 diabetes mellitus and chronic kidney disease. Medicine. 2026;105(41):e51019. doi:10.1097/MD.0000000000051019

Article Links: PubMed · Journal / DOI

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →